Skip to main content
  • New-Gen LVAD Improves on 2-Year Outcomes

    The centrifugal-flow HeartMate 3 left ventricular assist device (LVAD) was associated with better 2-year outcomes for advanced heart failure patients when compared with the older axial-flow HeartMate II pump, according to the MOMENTUM 3 trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details